Zacks: Tyme Technologies, Inc. (TYME) Given Consensus Recommendation of “Strong Buy” by Brokerages

Shares of Tyme Technologies, Inc. (NASDAQ:TYME) have earned a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three analysts have rated the stock with a strong buy rating.

Brokerages have set a 12-month consensus price target of $8.33 for the company and are predicting that the company will post ($0.06) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Tyme Technologies an industry rank of 176 out of 265 based on the ratings given to related companies.

TYME has been the topic of a number of research analyst reports. HC Wainwright initiated coverage on shares of Tyme Technologies in a research note on Friday, December 15th. They issued a “buy” rating and a $8.00 target price on the stock. BidaskClub upgraded shares of Tyme Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Evercore ISI assumed coverage on shares of Tyme Technologies in a research report on Friday, November 17th. They issued an “outperform” rating and a $7.00 price target on the stock. Finally, Canaccord Genuity assumed coverage on shares of Tyme Technologies in a research report on Wednesday, January 3rd. They issued a “buy” rating on the stock.

Tyme Technologies (TYME) traded down $0.34 during trading hours on Thursday, reaching $4.48. 154,895 shares of the company were exchanged, compared to its average volume of 180,200. Tyme Technologies has a 1-year low of $2.14 and a 1-year high of $9.50. The firm has a market cap of $447.50, a price-to-earnings ratio of -27.06 and a beta of -0.01.

Tyme Technologies (NASDAQ:TYME) last posted its earnings results on Thursday, November 2nd. The company reported ($0.06) earnings per share (EPS) for the quarter. equities research analysts forecast that Tyme Technologies will post -0.23 EPS for the current fiscal year.

In other Tyme Technologies news, COO Michael Demurjian sold 50,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $3.34, for a total value of $167,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

An institutional investor recently bought a new position in Tyme Technologies stock. Franklin Street Advisors Inc. NC purchased a new position in Tyme Technologies, Inc. (NASDAQ:TYME) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 31,000 shares of the company’s stock, valued at approximately $198,000. 2.45% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Zacks: Tyme Technologies, Inc. (TYME) Given Consensus Recommendation of “Strong Buy” by Brokerages” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark law. The original version of this story can be accessed at

Tyme Technologies Company Profile

Tyme Technologies, Inc is a clinical-stage biotechnology company. The Company is focused on developing cancer therapeutics that is intended to be broadly effective across tumor types and have low toxicity profiles. The Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.

Get a free copy of the Zacks research report on Tyme Technologies (TYME)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with's FREE daily email newsletter.

Leave a Reply